Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Yu-Hsing Fang, Tzu-Herng Hsu, Tzu-Yin Lin, Chia-Hung Liu, Shou-Chu Chou, Jie-Ying Wu & Pang-Chung Perng. (2021) Comparing intravenous peramivir with oral oseltamivir for patients with influenza: a meta-analysis of randomized controlled trials. Expert Review of Anti-infective Therapy 19:8, pages 1039-1046.
Read now
Read now
V.K. Tran-Nguyen, M.T. Le, T.D. Tran, V.D. Truong & K.M. Thai. (2019) Peramivir binding affinity with influenza A neuraminidase and research on its mutations using an induced-fit docking approach. SAR and QSAR in Environmental Research 30:12, pages 899-917.
Read now
Read now
Articles from other publishers (36)
Jeffrey J Cies, Wayne S MooreIIII, Daniel Marino, Jillian Deacon, Adela Enache & Arun Chopra. (2022) Oxygenator impact on peramivir in extra-corporeal membrane oxygenation circuits. Perfusion 38:3, pages 501-506.
Crossref
Crossref
Junhao Luo, Zhuohan Zhang, Song Zhao & Rongbao Gao. (2023) A Comparison of Etiology, Pathogenesis, Vaccinal and Antiviral Drug Development between Influenza and COVID-19. International Journal of Molecular Sciences 24:7, pages 6369.
Crossref
Crossref
Chengzhi Yu, Yayu Huang, Xin Ren & Leqiang Sun. (2023) Plant-derived Ren's oligopeptide has antiviral effects on influenza virus and SARS-CoV-2. Frontiers in Veterinary Science 9.
Crossref
Crossref
Maren Alchikh, Patrick E. Obermeier, Brunhilde Schweiger & Barbara A. Rath. (2023) Successful Treatment of Complicated Influenza A(H3N2) Virus Infection and Rhabdomyolysis with Compassionate Use of IV Zanamivir. Pharmaceuticals 16:1, pages 85.
Crossref
Crossref
Salsabila Zannuba Kurniawan, Riana Rahmawati, Fathiyatul Mudzkiroh, Muhammad Ariq Naufal Arofiq & Raden Muhammad Bagus Muliawan. 2023. Proceedings of the 3rd International Conference on Cardiovascular Diseases (ICCvD 2021). Proceedings of the 3rd International Conference on Cardiovascular Diseases (ICCvD 2021)
10
17
.
Wenjiao Wu, Chao Wang, Changliang Xia, Shuwen Liu & Qinghua Mei. (2022) MicroRNA let-7 Suppresses Influenza A Virus Infection by Targeting RPS16 and Enhancing Type I Interferon Response. Frontiers in Cellular and Infection Microbiology 12.
Crossref
Crossref
Mi-Seon Bang, Choon-Mee Kim, Dong-Min Kim & Na Ra Yun. (2022) Effective Drugs Against Severe Fever With Thrombocytopenia Syndrome Virus in an in vitro Model. Frontiers in Medicine 9.
Crossref
Crossref
Sphamandla E. Mtambo, Samuel C. Ugbaja, Aganze G. Mushebenge, Bahijjahtu H. Abubakar, Mthobisi L. Ntuli & Hezekiel M. Kumalo. (2022) Intermolecular Mechanism and Dynamic Investigation of Avian Influenza H7N9 Virus’ Susceptibility to E119V-Substituted Peramivir–Neuraminidase Complex. Molecules 27:5, pages 1640.
Crossref
Crossref
Marta Denel-Bobrowska & Agnieszka B. Olejniczak. (2022) Non-nucleoside structured compounds with antiviral activity—past 10 years (2010–2020). European Journal of Medicinal Chemistry 231, pages 114136.
Crossref
Crossref
Erika Bourguet, Sylwia Figurska & Manuela Maria Fra̧czek. (2022) Human Neuraminidases: Structures and Stereoselective Inhibitors. Journal of Medicinal Chemistry 65:4, pages 3002-3025.
Crossref
Crossref
Emanuele Palomba, Valeria Castelli, Giulia Renisi, Alessandra Bandera, Andrea Lombardi & Andrea Gori. (2021) Antiviral Treatments for Influenza. Seminars in Respiratory and Critical Care Medicine 42:06, pages 859-872.
Crossref
Crossref
Mostafa Javanian, Mohammad Barary, Sam Ghebrehewet, Veerendra Koppolu, VeneelaKrishnaRekha Vasigala & Soheil Ebrahimpour. (2021) A brief review of influenza virus infection. Journal of Medical Virology 93:8, pages 4638-4646.
Crossref
Crossref
William H. D. Bowles & Tracey M. Gloster. (2021) Sialidase and Sialyltransferase Inhibitors: Targeting Pathogenicity and Disease. Frontiers in Molecular Biosciences 8.
Crossref
Crossref
Tomoko Honda, Sumiko Gomi, Daisuke Yamane, Fumihiko Yasui, Takuya Yamamoto, Tsubasa Munakata, Yasushi Itoh, Kazumasa Ogasawara, Takahiro Sanada, Kenzaburo Yamaji, Yasuhiro Yasutomi, Kyoko Tsukiyama-Kohara & Michinori Kohara. (2021) Development and Characterization of a Highly Sensitive NanoLuciferase-Based Immunoprecipitation System for the Detection of Anti-Influenza Virus HA Antibodies. mSphere 6:3.
Crossref
Crossref
Eric J Chow, Richard H Beigi, Laura E Riley & Timothy M Uyeki. (2021) Clinical Effectiveness and Safety of Antivirals for Influenza in Pregnancy. Open Forum Infectious Diseases 8:6.
Crossref
Crossref
Yu‐Hsiang Hsieh, Andrea F. Dugas, Frank LoVecchio, Breana McBryde, Erin P. Ricketts, Kathryn Saliba‐Shaw & Richard E. Rothman. (2020) Intravenous peramivir vs oral oseltamivir in high‐risk emergency department patients with influenza: Results from a pilot randomized controlled study. Influenza and Other Respiratory Viruses 15:1, pages 121-131.
Crossref
Crossref
Ju Hwan Jeong, Won-Suk Choi, Khristine Joy C. Antigua, Young Ki Choi, Elena A. Govorkova, Richard J. Webby, Yun Hee Baek & Min-Suk Song. (2020)
In Vitro
Profiling of Laninamivir-Resistant Substitutions in N3 to N9 Avian Influenza Virus Neuraminidase Subtypes and Their Association with
In Vivo
Susceptibility
. Journal of Virology 95:1.
Crossref
Crossref
Vitória Rodrigues Guimarães Alves, Luciano Kleber de Souza Luna, Jessica Santiago Cruz, Ana Helena Perosa & Nancy Bellei. (2019) Influenza B viral load analysis in patients with acute respiratory infection from a tertiary hospital in Brazil. Journal of Medical Virology 92:8, pages 1350-1354.
Crossref
Crossref
Shane O'Sullivan, Antoni Torres, Alejandro Rodriguez & Ignacio Martin-Loeches. (2020) Influenza management with new therapies. Current Opinion in Pulmonary Medicine 26:3, pages 215-221.
Crossref
Crossref
Qianda Zou, Shufa Zheng, Xiaochen Wang, Sijia Liu, Jiaqi Bao, Fei Yu, Wei Wu, Xianjun Wang, Bo Shen, Tieli Zhou, Zhigang Zhao, Yiping Wang, Ruchang Chen, Wei Wang, Jianbo Ma, Yongcheng Li, Xiaoyan Wu, Weifeng Shen, Fuyi Xie, Dhanasekaran Vijaykrishna & Yu Chen. (2020) Influenza A-associated severe pneumonia in hospitalized patients: Risk factors and NAI treatments. International Journal of Infectious Diseases 92, pages 208-213.
Crossref
Crossref
Xuyun Peng, Yichun Xiao, Li Li, Dongxiang Wen, Xiaoyan Gong, Bingfei Li & Lili Zhou. (2020) Curative efficacy and safety of peramivir in the treatment of children suspected with influenza. European Journal of Inflammation 18, pages 205873922094613.
Crossref
Crossref
Wanqing Li, Abhishek Santra, Hai Yu, Teri J. Slack, Musleh M. Muthana, Dashuang Shi, Yang Liu & Xi Chen. (2019) 9-Azido-9-deoxy-2,3-difluorosialic Acid as a Subnanomolar Inhibitor against Bacterial Sialidases. The Journal of Organic Chemistry 84:11, pages 6697-6708.
Crossref
Crossref
Nicola Principi, Barbara Camilloni, Anna Alunno, Ilaria Polinori, Alberto Argentiero & Susanna Esposito. (2019) Drugs for Influenza Treatment: Is There Significant News?. Frontiers in Medicine 6.
Crossref
Crossref
Razan El Ramahi & Alison Freifeld. (2019) Epidemiology, Diagnosis, Treatment, and Prevention of Influenza Infection in Oncology Patients. Journal of Oncology Practice 15:4, pages 177-184.
Crossref
Crossref
Ryan O’Hanlon & Megan L Shaw. (2019) Baloxavir marboxil: the new influenza drug on the market. Current Opinion in Virology 35, pages 14-18.
Crossref
Crossref
Rob Lambkin-Williams, Nicolas Noulin, Alex Mann, Andrew Catchpole & Anthony S. Gilbert. (2018) The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics. Respiratory Research 19:1.
Crossref
Crossref
Grigorescu Cristina, Antoniu Sabina Antonela, Oţelea Marina Ruxandra, Ileana Antohe, Fildan Ariadna Petronela, Arghir Ioan Anton & Tofolean Ecaterina Doina. (2018) Antivirals for Virus Induced Exacerbations of Asthma and COPD Treatment. ARS Medica Tomitana 24:3, pages 152-156.
Crossref
Crossref
Yongbing Sun, Wei Gan, Mingdao Lei, Wei Jiang, Meng Cheng, Junwei He, Qi Sun, Wan Liu, Lvjiang Hu & Yi Jin. (2018) PEPT1-mediated prodrug strategy for oral delivery of peramivir. Asian Journal of Pharmaceutical Sciences 13:6, pages 555-565.
Crossref
Crossref
Ashley Roberts & Joanne M. Langley. 2018. Evidence-Based Infectious Diseases. Evidence-Based Infectious Diseases
193
199
.
Wenyang Wei, Haitong Wan, Xueqian Peng, Huifen Zhou, Yiyu Lu & Yu He. (2018) Antiviral effects of Ma Huang Tang against H1N1 influenza virus infection in vitro and in an ICR pneumonia mouse model. Biomedicine & Pharmacotherapy 102, pages 1161-1175.
Crossref
Crossref
H. Keipp Talbot. (2017) Influenza in Older Adults. Infectious Disease Clinics of North America 31:4, pages 757-766.
Crossref
Crossref
Bindumadhav M. Marathe, Heba H. Mostafa, Peter Vogel, Philippe Noriel Q. Pascua, Jeremy C. Jones, Charles J. Russell, Richard J. Webby & Elena A. Govorkova. (2017) A pharmacologically immunosuppressed mouse model for assessing influenza B virus pathogenicity and oseltamivir treatment. Antiviral Research 148, pages 20-31.
Crossref
Crossref
Clément Fage, Véronique Tu, Julie Carbonneau, Yacine Abed & Guy Boivin. (2016) Peramivir Susceptibilities of Recombinant Influenza A and B Variants Selected with Various Neuraminidase Inhibitors. Antiviral Therapy 22:8, pages 711-716.
Crossref
Crossref
Nancy Law & Deepali Kumar. (2017) Post-transplant Viral Respiratory Infections in the Older Patient: Epidemiology, Diagnosis, and Management. Drugs & Aging 34:10, pages 743-754.
Crossref
Crossref
Philippe Noriel Q. Pascua, Heba H. Mostafa, Bindumadhav M. Marathe, Peter Vogel, Charles J. Russell, Richard J. Webby & Elena A. Govorkova. (2017) Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection. Scientific Reports 7:1.
Crossref
Crossref
Jonghoo LeeJu-Hee ParkHyeyoung JwaYee Hyung Kim. (2017) Comparison of Efficacy of Intravenous Peramivir and Oral Oseltamivir for the Treatment of Influenza: Systematic Review and Meta-Analysis. Yonsei Medical Journal 58:4, pages 778.
Crossref
Crossref